Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer

NCT04624399 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT04624399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04624399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Neoadjuvant Immune Checkpoint Inhibitors in Urothelial Cancer
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Completed
Start date
June 17, 2021
Completion date
May 30, 2026
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

urogenital cancer